$SLRX News
Last published 10mo ago
- 10mo agoSLRXSalarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate TherapeuticsGlobeNewswireTrading under DCOY to commence on January 8, 2026 Company's proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient 2026 plan
- 10mo agoSLRXSalarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingGlobeNewswireHOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) ("Salarius" or the "Company") today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for
- 10mo agoSLRXSalarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate PlatformGlobeNewswireThe combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker "DCOY" effective in early January 2026 Company to focus on advancing lead antiviral programs,
- 11mo agoSLRXSalarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu StudyGlobeNewswireSalarius subsidiary Decoy Therapeutics' influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein, supporting
- 11mo agoSLRXSalarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX"GlobeNewswireHOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its common stock
- 12mo agoSLRXSalarius Pharmaceuticals and Decoy Therapeutics Complete MergerGlobeNewswireStrategic transaction supports the advancement of Decoy's rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™ platform Combined company has pro forma
- 12mo agoCRMDHUMAKBLBSLRXStrong Earnings and Biotech Resilience Define the Midweek MomentumGlobeNewswireDENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB:KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research
- 1y agoSLRXSalarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public OfferingPR NewswireSalarius Pharmaceuticals, Inc. ("Salarius" or the "Company") (NASDAQ: SLRX) today announced the pricing of an underwritten public offering for gross...
- 1y agoSLRXSalarius Pharmaceuticals Regains Compliance with All Nasdaq Listing RequirementsGlobeNewswireHOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq)
- 1y agoSLRXSalarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireHOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market LLC
- 1y agoSLRXSalarius Pharmaceuticals Announces 1-for-15 Reverse Stock SplitGlobeNewswireHOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 1y agoSLRXSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity StandardGlobeNewswireHOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC
- 1y agoSLRXSalarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory BoardGlobeNewswireCAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate
- 1y agoSLRXSalarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related VirusesGlobeNewswireCAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide-conjugate
- 1y agoSLRXSalarius Pharmaceuticals Reports 2024 Financial Results and Provides Business UpdateGlobeNewswireContemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and
- 1y agoSLRXSalarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic CancersGlobeNewswireHOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in
- 1y agoSLRXSalarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger AgreementGlobeNewswireDecoy's proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and
- 2y agoSLRXClinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual MeetingGlobeNewswirePatients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk
- 2y agoSLRXSalarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitGlobeNewswireHOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 2y agoSLRXSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswirePatient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant Expense-reduction Measures
- 2y agoSLRXSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesGlobeNewswireCompany implementing a series of cost-savings measures designed to extend Salarius' expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from the ongoing Phase 1/2
- 2y agoSLRXSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersGlobeNewswireExpands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan. 16, 2024 (GLOBE
- 2y agoSLRXInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentGlobeNewswireHOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer
- 3y agoSLRXSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramGlobeNewswireFDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months
- 3y agoSLRXSalarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its ResourcesGlobeNewswireHOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 3y agoSLRXSalarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsGlobeNewswireThe trial will assess the safety and preliminary efficacy of Salarius' novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a gene signature to
- 3y agoSLRXSalarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid CongressGlobeNewswireHOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 3y agoSLRXSalarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireHOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 3y agoSLRXSalarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireHOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 3y agoSLRXSalarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewswireFDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to discuss future development and potential registration pathways SP-3164 targeted protein degrader
- 3y agoSLRXFDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing SarcomaGlobeNewswireDecision Follows Review of Comprehensive Safety Data Package Submitted by the Company Salarius Plans to Meet with FDA to Discuss Future Development and Potential Registration Pathways HOUSTON, May 09, 2023 (GLOBE
- 3y agoSLRXSalarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164GlobeNewswireHOUSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 3y agoSLRXSalarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual MeetingGlobeNewswireSP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity in animal models of multiple myeloma Preclinical findings support the Company's planned
- 3y agoSLRXSalarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational ConferenceGlobeNewswireHOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 3y agoCNTXDPROMMMBSLRX+1Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023GlobeNewswireNEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Emerging Growth Invitational Investor Conference on
- 3y agoSLRXSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewswireData to be presented at AACR demonstrate significant SP-3164 anticancer activity in both non-Hodgkin Lymphoma and Multiple Myeloma cell lines and animal models Targeted protein degrader SP-3164 on track for IND
- 3y agoSLRXSalarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual MeetingGlobeNewswireHOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 3y agoSLRXSalarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone SymposiaGlobeNewswireHOUSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop
- 3y agoSLRXSalarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of TexasGlobeNewswireHOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 3y agoSLRXSalarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development SummitGlobeNewswirePreclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin's lymphomas, and significantly better performance than standard-of-care treatment Company plans to
- 3y agoSLRXSalarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development SummitGlobeNewswireDr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company planning to submit an Investigational New Drug application to the U.S. Food and Drug Administration and begin a Phase 1
- 3y agoSLRXSalarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein DegradersGlobeNewswireExpands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue Protein degrader intellectual property portfolio now includes 16 issued patents across six unique
- 3y agoSLRXInvestigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual MeetingGlobeNewswirePatients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among eight myelodysplastic syndrome (MDS) and chronic myelomonocytic
- 3y agoSLRXSalarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual MeetingGlobeNewswireSignificant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid®) Synergistic activity with rituximab in DLBCL mouse model
- 3y agoSLRXSalarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASHGlobeNewswireHOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 3y agoSLRXSalarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged SarcomasGlobeNewswire60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who
- 4y agoSLRXSalarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireHOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 4y agoSLRXSalarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual MeetingGlobeNewswireHOUSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for
- 4y agoSLRXSalarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation ConferenceGlobeNewswireData showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical results at the American Society of Hematology annual meeting
- 4y agoSLRXSalarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation ConferenceGlobeNewswireHOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for